Eyenovia to Participate in Two Upcoming Investor Conferences
March 04 2019 - 08:30AM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print delivery
technology, today announced that members of management will be
participating in two upcoming investor conferences.
Details of the presentation are as follows:
31st Annual ROTH
Conference.Date: Monday-Tuesday, March
18-19, 2019Format: 1x1
MeetingsLocation: The Ritz-Carlton, Laguna Niguel,
Dana Point, CA
29th Annual Oppenheimer Healthcare
ConferenceDate: Wednesday, March 20,
2019Format: Presentation and 1X1
MeetingsPresentation Time: 3:55-4:25
PMLocation: Westin New York Grand Central, New
York, NY
About EyenoviaEyenovia, Inc.
(NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical
company developing a pipeline of microdose therapeutics utilizing
its patented piezo-print delivery technology. Eyenovia’s pipeline
is currently focused on the late-stage development of microdosed
medications for mydriasis, myopia progression, glaucoma, and other
eye diseases. For more Information please visit
www.eyenovia.com.
About MicroStat for
MydriasisMicroStat is Eyenovia's first-in-class
fixed-combination micro-formulation product
(phenylephrine-tropicamide) candidate for pharmacologic mydriasis
(eye dilation) which is targeted to address the growing needs of
the estimated 80 million office-based comprehensive and diabetic
eye exams performed every year in the United States, as well as the
estimated 4 million pharmacologic mydriasis applications for
cataract surgery. We are developing MicroStat to help improve
efficacy, usability and tolerability of pharmacologic
mydriasis.
Feasibility Dose-finding Studies: MicroStat Ph
I/II; MicroStat Ph IIUpcoming Milestone: NDA Filing In Q1 2020
About MicroPine for Progressive
MyopiaMicroPine is Eyenovia's first-in-class topical
treatment for progressive myopia, a back-of-the-eye disease.
Progressive myopia is estimated to affect close to 5 million
patients in the United States who suffer from uncontrolled axial
elongation of the sclera leading to increasing levels of myopia and
in some cases major pathologic changes such as retinal atrophy,
macular staphylomas, retinal detachment and visual impairment.
Early dose finding studies by collaborative academic groups have
demonstrated high therapeutic potential with low dose atropine
which can reduce myopia progression by 60 – 70% with a sustained
effect through three years. A recent therapeutic evidence
assessment and review by the American Academy of Ophthalmology
indicates Level 1 (highest) evidence of efficacy for the role of
low dose atropine for progressive myopia (Ophthalmology
2017;124:1857-1866; Ophthalmology 2016; 123(2)
391:399).
Feasibility Dose-finding Atropine Studies:
ATOM 1; ATOM 2 (Independent
Collaborative Group Trials) Upcoming Milestone: MicroPine Phase III
Trial First Patient In 2019
About MicroProst for
GlaucomaMicroProst is Eyenovia's proprietary latanoprost
formulation product candidate, which is being developed as a
first-line treatment for the reduction of IOP in patients with
Chronic Angle Closure Glaucoma (CACG), as well as Ocular
Hypertension and Primary Open Angle Glaucoma (POAG). Currently,
there are no FDA-approved therapies specifically indicated for
CACG, which accounts for an estimated 10% and 50% of all glaucoma
diagnoses in the United States and China, respectively. We believe
there are close to 700,000 patients with CACG in the United States
and more than 3.5 million with POAG for whom chronic, often
life-long medication therapy is required. Feasibility Dose-Finding
Studies: MicroProst Phase II PG21Upcoming
Milestone: MicroProst Phase III Trial First Patient In 2019
About MicroTears OTC for Dry
EyeMicroTears is a micro-droplet ocular surface tear
replenishment product candidate for the estimated $2 billion+ (200
million units) global annual OTC artificial tear market.Upcoming
Milestone: OTC Registration 2019
About Optejet™ and MicroRx Ocular
TherapeuticsEyenovia's Optejet microdose formulation and
delivery platform for ocular therapeutics uses high-precision
piezo-print technology to deliver 6 – 8 μL of drug, consistent with
the capacity of the tear film of the eye. We believe the volume of
ophthalmic solution administered with the Optejet is less than 75%
of that delivered using conventional eyedroppers, thus reducing
overdosing and exposure to drug and preservatives. Eyenovia's
patented microfluidic ejection technology is designed for fast and
gentle ocular surface delivery in less than 80 milliseconds beating
the ocular blink reflex. The Optejet's targeted delivery system has
demonstrated 85% topical delivery efficacy compared to 40-50% with
the conventional eyedropper, and its smart electronics and mobile
e-health technology are designed to track and enhance patient
compliance.
Company Contact:Eyenovia,
Inc.John GandolfoChief Financial
Officerjgandolfo@eyenoviabio.com
Investor Contact:Tram Bui /
Alexander LoboThe Ruth Group646-536-7035/7037tbui@theruthgroup.com
/ alobo@theruthgroup.com
Media Contact:The Ruth
GroupKirsten Thomas508-280-6592kthomas@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Mar 2023 to Mar 2024